Stem Cells for COVID-19 ARDS

Published 2020-09-16

A clinical trial led by Michael Matthay, M.D. at the University of California, San Francisco is exploring the potential of Bone Marrow derived Mesenchymal Stem Cells (MSCs) for COVID-19 pneumonia related Adult Respiratory Distress Syndrome (ARDS). In the treatment arm of the study, patients will receive two intravenous infusions of 2 million MSCs/kg. The study is anticipated to enroll 300 patients in total.

Search our Directory

AABRM Members are not only experts in regenerative medicine but offer a wide range of related products, services and related-procedures in that field. Search our extensive Member Directory to find a Member near you.

Member Directory

American Society of Regenerative Medicine Logo

Excellence.  Education.  Research.  Practice.